Raymond James Financial’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$341M Buy
11,943,333
+1,279
+0% +$34K 0.09% 191
2026
Q2
$288M Buy
11,942,054
+267,838
+2% +$7.01M 0.08% 219
2026
Q1
$328M Buy
11,674,216
+187,503
+2% +$4.99M 0.1% 175
2025
Q4
$286M Sell
11,486,713
-9,541
-0.1% -$241K 0.09% 197
2025
Q3
$293M Buy
11,496,254
+710,057
+7% +$17.5M 0.09% 194
2025
Q2
$261M Sell
10,786,197
-101,080
-0.9% -$2.36M 0.09% 206
2025
Q1
$276M Buy
10,887,277
+533,173
+5% +$14M 0.1% 183
2024
Q4
$275M Buy
+10,354,104
New +$281M 0.1% 182

Other funds holding PFE

Raymond James Financial's PFE Position: Q3 2026 in Review

Raymond James Financial increased its Pfizer (PFE) stake by 0.01% in Q3 2026, buying an estimated $34K and bringing the position to 11,943,333 shares worth $341M. The position accounts for 0.09% of the portfolio, ranked #191.

Raymond James Financial first reported a position in PFE in Q4 2024 and has held it in 8 quarters since. 2,556 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Raymond James Financial held 11,943,333 shares of Pfizer worth $341M as of Q3 2026.
  • Raymond James Financial bought 1,279 Pfizer shares in Q3 2026, an estimated $34K.
  • Pfizer made up 0.09% of Raymond James Financial's portfolio in Q3 2026, its #191 holding.
  • Raymond James Financial first reported a position in Pfizer in Q4 2024 and has held it in 8 quarters since.
  • 2,556 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.